microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.

about

microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.

Item

http://www.wikidata.org/entity/Q47128749

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

microRNA-193a-3p is specifical ...... RAF-mutated colorectal cancer.

@en

microRNA-193a-3p is specifical ...... RAF-mutated colorectal cancer.

@nl

type

Item

label

microRNA-193a-3p is specifical ...... RAF-mutated colorectal cancer.

@en

microRNA-193a-3p is specifical ...... RAF-mutated colorectal cancer.

@nl

prefLabel

microRNA-193a-3p is specifical ...... RAF-mutated colorectal cancer.

@en

microRNA-193a-3p is specifical ...... RAF-mutated colorectal cancer.

@nl

P1476

microRNA-193a-3p is specifical ...... RAF-mutated colorectal cancer.

@en

P2093

Chikashi Ishioka

http://www.w3.org/2001/XMLSchema#string

Hidekazu Takahashi

http://www.w3.org/2001/XMLSchema#string

Hideki Shimodaira

http://www.w3.org/2001/XMLSchema#string

Kota Ouchi

http://www.w3.org/2001/XMLSchema#string

Masanobu Takahashi

http://www.w3.org/2001/XMLSchema#string

Michiaki Unno

http://www.w3.org/2001/XMLSchema#string

Shin Takahashi

http://www.w3.org/2001/XMLSchema#string

Shinobu Ohnuma

http://www.w3.org/2001/XMLSchema#string

Yasuhide Yamada

http://www.w3.org/2001/XMLSchema#string

Yuki Yoshino

http://www.w3.org/2001/XMLSchema#string

P2860

MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma

CpG island methylator phenotype in colorectal cancer

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.

Mutations of the BRAF gene in human cancer

P2888

s12885-017-3739-x

P304

723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-017-3739-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092578249

http://www.w3.org/2001/XMLSchema#string

P698

29115941

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

microRNA

P932

5678600

http://www.w3.org/2001/XMLSchema#string